Safety,Efficacy,and Economic Evaluation of Trastuzumab Biosimilars in the Treatment of HER2-Positive Advanced Breast Cancer
Objective To compare the safety,efficacy,and economics of the trastuzumab biosimilar Zercepac(HLX02)versus the original drug Herceptin in the treatment of patients with human epidermal growth factor receptor 2(HER2)-positive breast cancer.Methods The clinical data of 56 HER2-positive advanced breast cancer patients who received trastuzumab combined with paclitaxel chemotherapy in the First Affiliated Hospital of Nanchang University,Jiangxi Cancer Hospital and the Third Hospital of Nanchang City from August 2020 to December 2022 were retrospectively analyzed.The patients were divided into the observation group(n=22,treated with HLX02)and the control group(n=34,treated with Herceptin)according to different treatment schemes,and the efficacy,adverse reactions and medical cost in the two groups were compared.Results In terms of efficacy,the median progression-free survival in the observation group was 15.8 months[95％CI(7.34,24.27)],which was not significantly different from 12.5 months[95％CI(8.72,16.31)]in the control group(P=0.466);the objective remission rate in the observation group was 54.55％,which was not significantly different from 52.94％in the control group(P=0.906);the disease control rate in the observation group was 90.91％,which was not significantly different from 88.24％in the control group(P=1.000).In terms of safety,the incidence of adverse reactions between the observation group and the control group was comparable(83.36％vs.73.53％,P=0.418).In terms of economics,the median total medical cost in the observation group was CNY 13 991.08,which was lower than CNY 17 553.69 in the control group,but there was no significant difference(P=0.131).Conclusion The efficacy,safety,and economics of HLX02 and Herceptin are comparable.But HLX02 has a specification advantage,and physicians can choose the appropriate drug based on the patient's dosage.
trastuzumabhuman epidermal growth factor receptor 2-positive breast cancerefficacysafetyeconomics
万方数据
维普
